|
PurposeTo evaluate the response rate, toxicity, clinical benefit response, time to disease progression and one-year survival rate of S-1 Combined paclitaxel for advanced gastric cancer patients.Methods43 cases of advanced gastric cancer patients diagnosed by histopathology or cytology were randomized into the two groups. In the trial group, S-1 was administered orally twice daily at a standard dose of 80 mg/m2 per day for 14 consecutive days and paclitaxel(60mg/m2) was given intravenously on day 1,8,15 for a cycle of four weeks. In the control group, 5-Fu (500mg/m2) and CF (20mg/m2) were given intravenously on days 1~5, paclitaxel(60mg/m2) was given intravenously on day 1,8,15 for a cycle of four weeks. After two cycles, the response rate, toxicity, clinical benefit response, time to disease progression and one-year survival rate were compared and analyzed between the two groups.ResultsA total of 22 cases of trial group and 21 cases of control group advanced gastric cancer patients have been treated, one of the control group patient exited (quitting because of IV myelosuppression), and did not conduct evaluation, but evaluation for toxicity. Finally the number of patients can be evaluated for 22 cases of the trial group, and 20 cases of the control group. (1) The response rate were 54.5% in the trial group and 30.0% in the control group (P>0.05), The benefit response rates were 77.3% in the trial group and 45% in the control group(P<0.05).The incidence of leucopenia was 50.0% in the trial group and 47.6% in the control group(P>0.05), The incidence of anemia was 22.7% in the trial group and 19.0% in the control group, The incidence of thrombocytopenia was 18.2% in the trial group and 23.8% in the control group(P>0.05). Non-hematologic toxicity test group and control group of nausea and vomiting incidence were 27.3% and 61.9%, compared the two groups has statistical significance (P<0.05). (2) the median time to disease progression were 6.5 months (195 days) in the trial group and 6.3months (189 days) in the control group , the two groups have no statistical significance.ConclusionsS-1 combined paclitaxel have no statistical differences compared with 5-Fu combined paclitaxel in the response rate, and well tolerated for advanced gastric cancer patients. It is worth further clinical studies.
|